PH12022553129A1 - Compositions and methods for treating cancer - Google Patents

Compositions and methods for treating cancer

Info

Publication number
PH12022553129A1
PH12022553129A1 PH1/2022/553129A PH12022553129A PH12022553129A1 PH 12022553129 A1 PH12022553129 A1 PH 12022553129A1 PH 12022553129 A PH12022553129 A PH 12022553129A PH 12022553129 A1 PH12022553129 A1 PH 12022553129A1
Authority
PH
Philippines
Prior art keywords
methods
compositions
treating cancer
chimeric binding
same
Prior art date
Application number
PH1/2022/553129A
Other languages
English (en)
Inventor
David Cheresh
Stephen Mccormack
Christoph Rader
Sara Weis
Hiromi Wettersten
Original Assignee
Alpha Beta Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha Beta Holdings Llc filed Critical Alpha Beta Holdings Llc
Publication of PH12022553129A1 publication Critical patent/PH12022553129A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PH1/2022/553129A 2020-04-23 2021-04-23 Compositions and methods for treating cancer PH12022553129A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063014550P 2020-04-23 2020-04-23
PCT/US2021/028775 WO2021216956A1 (en) 2020-04-23 2021-04-23 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
PH12022553129A1 true PH12022553129A1 (en) 2024-02-26

Family

ID=78270118

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/553129A PH12022553129A1 (en) 2020-04-23 2021-04-23 Compositions and methods for treating cancer

Country Status (12)

Country Link
US (1) US20230140868A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110822A4 (cg-RX-API-DMAC7.html)
JP (1) JP7817948B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230019424A (cg-RX-API-DMAC7.html)
CN (1) CN115485301A (cg-RX-API-DMAC7.html)
AU (1) AU2021261003A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019939A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172092A1 (cg-RX-API-DMAC7.html)
IL (1) IL296576A (cg-RX-API-DMAC7.html)
MX (1) MX2022013207A (cg-RX-API-DMAC7.html)
PH (1) PH12022553129A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021216956A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102423686B1 (ko) * 2019-01-10 2022-07-21 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
US12319732B2 (en) 2019-01-10 2025-06-03 Sg Medical Inc. Anti-beta 1 integrin humanized antibody, and pharmaceutical composition for treating cancer, comprising same
WO2023056326A1 (en) * 2021-09-30 2023-04-06 Alpha Beta Holdings, Llc Compositions and methods for treating cancer
CN118542937A (zh) * 2023-02-24 2024-08-27 恒翼生物医药(上海)股份有限公司 抗αvβ3抗体和抗PD-1抗体的联合药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
JP2002508656A (ja) 1997-03-12 2002-03-19 スミスクライン・ビーチャム・コーポレイション 抗−アルファベータ3ヒト化モノクローナル抗体
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
CA2436326C (en) * 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
NO2699601T3 (cg-RX-API-DMAC7.html) * 2011-04-21 2018-06-16
LT2884999T (lt) * 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
MX2015013163A (es) * 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
WO2015134988A1 (en) * 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
US9650441B2 (en) 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
US20200109205A1 (en) * 2017-03-31 2020-04-09 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
BR112022001273A2 (pt) * 2019-08-02 2022-06-07 Univ California Composições e métodos para direcionar e matar células tronco cancerosas (cscs) positivas para alfa-v beta-3 (avss3) (cscs) e tratar cânceres metastáticos e resistentes a fármacos

Also Published As

Publication number Publication date
EP4110822A4 (en) 2024-04-10
EP4110822A1 (en) 2023-01-04
AU2021261003A1 (en) 2022-10-20
MX2022013207A (es) 2023-01-24
JP2023523016A (ja) 2023-06-01
BR112022019939A2 (pt) 2022-12-13
WO2021216956A1 (en) 2021-10-28
CA3172092A1 (en) 2021-10-28
IL296576A (en) 2022-11-01
US20230140868A1 (en) 2023-05-11
CN115485301A (zh) 2022-12-16
KR20230019424A (ko) 2023-02-08
JP7817948B2 (ja) 2026-02-19

Similar Documents

Publication Publication Date Title
MX2022013207A (es) Metodos y composiciones para el tratamiento de cancer.
EP4512478A3 (en) Treatment of cancer
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2019012038A (es) Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
PH12022551462A1 (en) Ilt3-binding agents and methods of use thereof
DK1896507T3 (da) Anti-CD71-monoklonale antistoffer og anvendelser deraf til behandling af maligne tumorceller
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
MX2011009220A (es) Anticuerpos completamente humanos especificos para la molecula de adhesion celular 1.
MX2022013259A (es) Composiciones y metodos de tratamiento del cancer con receptores de antigeno quimerico.
PH12020500664A1 (en) C3-binding agents and methods of use thereof
MX2022015475A (es) Proteina de fusion que comprende il-12 y anticuerpo anti-fap, y uso de la misma.
MX2020000414A (es) Composicion de vacuna de neoantigeno para el tratamiento del cancer.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
MX2023005180A (es) Compuestos de union a il-2r\03b2?c y usos de estos.
ZA202204730B (en) Oligonucleotides with nucleoside analogs
MX2024014830A (es) Compuestos de degradacion de wee1 y usos de los mismos
MX2022002607A (es) Metodos de tratamiento.
IL327310A (en) Cancer treatment vehicles
WO2022036065A3 (en) Compositions and methods for treating cancers
MX2025000053A (es) Anticuerpos monoclonales anti-slc34a2 y sus usos
MX2022011027A (es) Composiciones y metodos para el tratamiento del cancer.
MX2020009829A (es) Composiciones farmaceuticas de saposina c y metodos para tratar el cancer.
ZA202108422B (en) Anti-cd25 for tumour specific cell depletion
IN2015KN00569A (cg-RX-API-DMAC7.html)
WO2022125578A3 (en) Methods of nk cell engineering to enhance tumor targeting